Opinion

Video

R/R DLBCL: Safety Considerations for Bispecific Antibodies

Author(s):

Sonali Smith, MD,Krish Patel, MD

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Related Content
Acute Myeloid Leukemia | stock.adobe.com
December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com
December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT